🏅 FDA Orphan Designation

Curosurf

Pulmonary surfactant replacement, porcine

Manufacturer: Chiesi USA, Inc.

Indicated for:

Infant acute respiratory distress syndromeOrphan

FDA-Approved Indications (1)

Infant acute respiratory distress syndromeOrphan Designation

Treatment (rescue) of respiratory distress syndrome in premature infants.

Indications & Usage

1 INDICATIONS AND USAGE CUROSURF ® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS. CUROSURF is a surfactant indicated for the rescue treatment, including the reduction of mortality and pneumothoraces, of Respiratory Distress Syndrome (RDS) in premature infants. ( 1 )

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.